All In MedTech

Device Trial Radar · NCT02099435

Study of Hemospray for Lower Gastrointestinal Hemorrhage

A Prospective Observational Cohort Study of Hemospray for Lower Gastrointestinal Hemorrhage (APPROACH LGI)

Last checked: Nov 19, 2026Latest source record: Jan 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Jan 2015

Primary completion

Nov 6, 2016

Study completion Nov 6, 2016

Sponsor

Lead sponsor
Cook Group IncorporatedNot on our public-company list
Sponsor type
Industry
First posted
Mar 28, 2014

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the performance of Hemospray for the teatment of nonvariceal lower gastrointestinal bleeding.

Conditions

  • Colonic Diverticula
  • Angiodysplasia
  • Colonic Polyp

Interventions

  • HemosprayDevice

    The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of device related adverse eventsTime frame: 30 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Alexandra Hospital

    Edmonton, Alberta, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Hotel Dieu Hospital

    Kingston, Ontario, Canada

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.